The NCI Lymphoma Steering Committee (LYSC) was established in 2009. At monthly meetings, it addresses the design, prioritization, and evaluation of concepts for phase II and phase III clinical trials in adult lymphoma. View the LYSC member roster as of November 7, 2025. The committee may periodically hold clinical trials planning meetings (CTPMs) to focus on specific clinical trial related topics.
Committee Highlights
The following are highlights from recent committee activities:
- Advancing Treatment of Major Lymphoma Subtypes
A CTPM was organized in 2014 to discuss current understanding of the major lymphoma subtypes, to identify unmet needs in the treatment of those diseases, and chart the clinical research agenda in lymphoma for the next five years. Read the executive summary and the following publications that are important outcomes of this CTPM:- Recent Advances in Characterization and New Opportunities for Treatment of T-Cell Lymphoma; JNCI
- Current Status and Clinical Trial Recommendations for Hodgkin Lymphoma; JNCI
- Recommendations for Clinical Trial Development in Follicular Lymphoma; JNCI
- Recommendations for Clinical Trial Development in Mantle Cell Lymphoma; JNCI
- A Blueprint for Diffuse Large B-Cell Lymphoma Research; JNCI
- Biomarker Recommendations for Lymphoma; JNCI
Contact
For more information, contact NCI CCCT Program Director, Elena Schwartz, Ph.D., M.S., at elena.schwartz@nih.gov.